The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001033336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/04/2026
Date registered
Help: Date registered
21/08/2026
Date last updated
Help: Date last updated
21/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/08/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A study evaluating SIR4156 together with semaglutide to reduce body fat in adults with obesity
Scientific title
A Phase II Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of SIR4156 in Combination with Semaglutide on Total Body Fat Mass and Body Composition in Adults with Obesity
Additional trial identifiers [1] 317347 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Obesity 341733 0
Condition category
Condition code
Metabolic and Endocrine 337804 337804 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants in the intervention arm will receive SIR4156 oral tablets administered twice daily in combination with semaglutide administered as a once-weekly subcutaneous injection for 24 weeks. Participants will receive either 100 mg or 200 mg SIR4156 according to the protocol-defined randomised treatment assignment. Semaglutide dosing will be escalated according to the approved product schedule: 0.25 mg once weekly for Weeks 1–4, 0.5 mg once weekly for Weeks 5–8, 1.0 mg once weekly for Weeks 9–12, 1.7 mg once weekly for Weeks 13–16, and 2.4 mg once weekly from Week 17 onwards as the maintenance dose, as tolerated. Semaglutide injections will be self-administered by participants following training provided by the study team. Adherence to study treatment will be monitored throughout the study using participant dosing diaries, study drug accountability records, and reconciliation of returned study medication at each study visit. Participants will receive instructions on study treatment administration and diary completion, with compliance reviewed by site staff at scheduled visits.
Intervention code [1] 333917 0
Treatment: Drugs
Description of the comparator or control
Participants in the control arm will receive placebo tablets matching SIR4156 in appearance, packaging, and administration schedule administered twice daily in combination with semaglutide administered as a once-weekly subcutaneous injection for 24 weeks. Semaglutide dosing will follow the protocol-specified dose escalation schedule up to the target maintenance dose specified in the protocol. The placebo tablets contain inactive excipients only.
Control group
Placebo

Outcomes
Primary outcome [1] 345254 0
Percent change from baseline in total body fat mass
Timepoint [1] 345254 0
Baseline and Week 24 post-baseline
Secondary outcome [1] 461119 0
Safety
Timepoint [1] 461119 0
The assessments will be conducted at Baseline and then every 4 weeks through Week 24.
Secondary outcome [2] 464065 0
Tolerability
Timepoint [2] 464065 0
Treatment-emergent adverse events will be assessed continuously from the first dose through Week 24. Treatment discontinuations, dose interruptions, dose reductions and investigator clinical assessments will be assessed at Baseline and at approximately 4-weekly study visits through Week 24.
Secondary outcome [3] 465425 0
Pharmacokinetics of SIR4156
Timepoint [3] 465425 0
Pharmacokinetic assessments will be performed at Baseline (Day 1), Weeks 4, 8, 16 and 24, with an additional assessment at Early Termination, if applicable.
Secondary outcome [4] 465426 0
Pharmacodynamic Effects
Timepoint [4] 465426 0
Week 24 (Baseline of the Maintenance Phase), Week 32, Week 40, Week 48 (End of Treatment), and Early Termination (if applicable).

Eligibility
Key inclusion criteria
Adults aged 18 to 75 years with obesity defined as body mass index greater than or equal to 30 kilograms per square meter, with stable body weight prior to screening, and able to comply with study procedures.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants with diabetes mellitus, use of weight loss medications within a recent period prior to screening, significant cardiovascular, hepatic or renal disease, pregnancy or breastfeeding, or any condition that in the opinion of the investigator would make participation unsafe or interfere with study results.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be implemented through a centralised Interactive Response Technology (IRT) system. Participant treatment assignments will be generated according to a computer-generated randomisation schedule and assigned through the IRT system at the time of randomisation. Treatment allocation will remain concealed from participants, investigators, study site personnel, and Sponsor personnel involved in study conduct throughout the study, unless emergency unblinding is required for participant safety.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated randomisation sequence
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC

Funding & Sponsors
Funding source category [1] 319944 0
Commercial sector/Industry
Name [1] 319944 0
Sironax Ltd.
Country [1] 319944 0
China
Primary sponsor type
Commercial sector/Industry
Name
Sironax Aus Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324571 0
None
Name [1] 324571 0
Address [1] 324571 0
Country [1] 324571 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318480 0
Bellberry Human Research Ethics Committee K
Ethics committee address [1] 318480 0
Ethics committee country [1] 318480 0
Australia
Date submitted for ethics approval [1] 318480 0
18/03/2026
Approval date [1] 318480 0
22/04/2026
Ethics approval number [1] 318480 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 144334 0
Dr Yair Edinburg
Address 144334 0
Paratus Clinical Research, 48 High Street, Northcote, VIC, Australia
Country 144334 0
Australia
Phone 144334 0
+61 02 8203 7900
Fax 144334 0
Email 144334 0
Contact person for public queries
Name 144335 0
Dr. Yair Edinburg
Address 144335 0
Paratus Clinical Research, 48 High Street, Northcote, VIC
Country 144335 0
Australia
Phone 144335 0
+61 2 8203 7900
Fax 144335 0
Email 144335 0
Contact person for scientific queries
Name 144336 0
Valon Latifi
Address 144336 0
Sironax, Level 40, 2–26 Park Street, Sydney NSW 2000,
Country 144336 0
Australia
Phone 144336 0
+61 401208760
Fax 144336 0
Email 144336 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.